Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Oncimmune Holdings ( (GB:ONC) ) has issued an update.
Oncimmune Holdings has announced the posting of a notice of a General Meeting to shareholders, which will occur on March 10, 2025, to approve the company’s Annual Report and Accounts for the financial year ending August 31, 2024. This meeting is significant as it will address the company’s financial performance and strategic direction, impacting stakeholders and potentially influencing future collaborations and market positioning.
More about Oncimmune Holdings
Oncimmune Holdings is a precision medicine company that specializes in analyzing immune interactions through autoantibody profiling. It partners with global pharmaceutical and biotech companies, as well as contract research organizations, to discover novel biomarkers for developing targeted and effective therapies for immune-mediated diseases. Oncimmune’s mission is to enable precision medicine through its platform, which aids in discovering novel biomarkers and predicting treatment efficacy. The company is headquartered in the UK, with a discovery and development facility in Dortmund, Germany, and a business development team in the US and Europe.
YTD Price Performance: -46.86%
Average Trading Volume: 164,750
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £9.7M
Find detailed analytics on ONC stock on TipRanks’ Stock Analysis page.